Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 82

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 82
---
. As of June 30, 2025, we had cash and cash equivalents of $33.4 million. We
anticipate that operating losses and net cash used in operating activities will increase over the next few years as we advance our products
under development.

During the six months ending
June 30, 2025, the Company sold 1,304,707 shares of common stock at an average price of $8.01 for gross proceeds of approximately $10.4
million under the ATM offering.

During June 2025, the Company
entered into securities purchase agreements with investors whereby the Company sold 3,000,000 shares of the common stock in a registered
direct offering in exchange for gross proceeds of $18.9 million (net proceeds of approximately $17.4 million).

Our
primary uses of capital are, and we expect will continue to be, third-party clinical and preclinical research and development services,
costs incurred to manufacture our drugs under development, compensation and related expenses, legal, patent and other regulatory expenses
and general overhead costs. We believe our use of CROs provides us with flexibility in managing our spending.

The
Company incurs significant research and development expenses in Australia and the United Kingdom. Fluctuations in the rate of exchange
between the United States dollar and the pound sterling as well as the Australian dollar could adversely affect our financial results,
including our expenses as well as assets and liabilities. We currently do not hedge foreign currencies but will continue to assess whether
that strategy is appropriate. As of June 30, 2025, the cash balance held by our foreign subsidiaries with currencies other than the United
States dollar was approximately $0.2 million.

Our recurring net losses and negative cash flows from operations, as
well as forecast of continued losses and negative cash flows from operations, raised substantial doubt regarding our ability to continue
as a going concern within one year after the issuance of our unaudited condensed consolidated financial statements for the six months
ended June 30, 2025. Until we can generate sufficient revenue from the commercialization of our product candidates, we expect to finance
our operations through the public or private sale of equity, debt financing or other capital sources, such as government funding, collaborations,
strategic alliances, divestment of non-core assets, or licensing arrangements with third parties. Our cash and cash equivalents were $33.4
million and total current assets were $36.0 million at June 30,